Asarfi Hospital Limited · BSE:ASARFI
Asarfi Hospital — FY2026 Earnings Presentation
35 slides from Asarfi Hospital's earnings presentation, May 11, 2026
Slide 1: BSE Filing Letter: Investor Presentation
असफ हॉ ीटल सबके िलए ा AHL/AO/2026/1183 Date: 11.05.2026 To, The Listing Department BSE Limited 25th Floor, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400001 Sub: Investor Presentation Ref: Scrip Code: 543943 Dear Sir/Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of Indi
Slide 2: Investor Presentation FY 2025-26
20+ Years Trust | Quality | Care Leading Healthcare Provider in Eastern India Investor Presentation FY 2025-26
Slide 3: Disclaimer
Disclaimer Certain matters discussed in this presentation may contain statements regarding the company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements do not guarantee future performance and are subject to
Slide 4: Q4'FY26 and FY26 Highlights
Q4’FY26 and FY26 Highlights 3
Slide 5: Quarterly Snapshot – Q4'FY26
Quarterly Snapshot – Q4’FY26 Q4’FY26 Revenue Q4’FY26 EBITDA Q4’FY26 EBITDA Margin Q4’FY26 PAT Rs 45.2 Cr(+10% 130 Cr (+29%YoY) YoY) Rs 130 Rs 7.7 Cr (+23% (+10% YoY) YoY) Rs 130 17% Cr (+10% YoY) Rs130 Rs 3.9 Cr (+10% (+9% YoY) YoY) VsVs RsRs 120CrCrininQ4’FY25 35.1 FY25 VsVsRsRs6.3 120CrCr in in FY
Slide 6: Quarterly Profit and Loss Summary
Quarterly Profit and Loss Summary Standalone (₹ in Lakhs) Consolidated (₹ in Lakhs) Particulars Q4'FY25* Q3'FY26 Q4'FY26 QoQ % YoY% Particulars Q4'FY25* Q3'FY26 Q4'FY26 QoQ % YoY% Revenue from operations 3,510 4,606 4,503 -2% 28% Revenue from operations 3,510 4,610 4,524 -2% 29% Material costs (750)
Slide 7: Quarterly Highlights – Q4'FY26
Quarterly Highlights – Q4’FY26 Financials (Standalone): IPD-OPD Revenues (₹ in lakhs): Revenue Growth YoY EBITDA Margin 3,751 28% 17% to ₹45 Cr in Q4’FY26 in Q4’FY26 2,440 (vs ₹35 Cr in Q4’FY25) (vs 18% in Q4’FY25) 54% YoY Growth in IPD Revenues 927 708 EBIT Margin PAT Margin 13% 9% Q4'FY25 Q4'FY26
Slide 8: Key Financial Parameters Over The Period - Standalone
Key Financial Parameters Over The Period - Standalone Revenue (₹ in Lakhs) EBITDA (₹ in Lakhs) and Margin % +42% 4,000 21% 21% 16,000 +28% 3,500 3,000 22% 12,000 18% 17% 2,500 2,000 8,000 1,500 12,178 17,320 4,000 1,000 2,506 3,551 4,606 4,503 1,012 3,510 786 500 646 0 0 Q4'FY25 Q3'FY26 Q4'FY26 FY25
Slide 9: Key Financial Parameters Over The Period - Consolidated
Key Financial Parameters Over The Period - Consolidated Revenue (₹ in Lakhs) EBITDA (₹ in Lakhs) and Margin % +42% 4,000 20% 20% 16,000 +29% 3,500 3,000 22% 12,000 17% 2,500 18% 2,000 8,000 1,500 1,000 12,178 17,350 4,000 1,011 2,476 3,528 4,524 4,610 3,510 772 500 629 0 0 Q4'FY25 Q3'FY26 Q4'FY26 FY
Slide 10: Revenue Mix – Q4'FY26 vs Q4'FY25 (Super-Specialty)
Revenue Mix – Q4’FY26 vs Q4’FY25 Super-Specialty Hospital Unit Q4'FY26 YoY Revenue Growth % by Specialty Cardiology Cardiology 36.3% 15% General Medicine General Medicine 16.0% 25% Neurosciences 58.4% Neurosciences 5% General Surgery General Surgery 50.1% 5% Paediatrics and Neonatology 76.2% Q4’FY26
Slide 11: Revenue Mix – Q4'FY26 vs Q4'FY25 (Cancer Hospital)
Revenue Mix – Q4’FY26 vs Q4’FY25 Cancer Hospital Unit Q4'FY26 YoY Revenue Growth % by Specialty -43% Medical Oncology 21% Medical Oncology Surgical Oncology 49% -71% Surgical Oncology Q4’FY26 Radiation Oncology 20% Others* Radiation Oncology 12% 10% 6% Revenue Contribution by Reasons for Decrease in
Slide 12: IPD-OPD Highlights (Both Hospital Units)
IPD-OPD Highlights (Both Hospital Units) IPD-OPD Volumes IPD-OPD Revenues (₹ in Lakhs) +29% IPD +21% OPD +46% IPD +34% OPD 1,60,000 16,000 14,460 1,37,689 1,40,000 +23% IPD 14,000 +54% IPD +11% OPD -24% OPD 1,20,000 1,14,215 12,000 9,909 1,00,000 10,000 80,000 8,000 60,000 51,717 6,000 34,160 3,817
Slide 13: Unit-wise ARPOB, Bed Capacity and Occupancy %
Unit-wise ARPOB, Bed Capacity and Occupancy % Super-Specialty Hospital Unit ARPOB (in ₹) Reasons for Increase in ARPOB (Q4 vs Q3) Bed Capacity and Occupancy % in Super-Specialty Unit: +24% 62% 61% 56% 61% 56% +32% 30,000 300 Higher revenue realization, Enhanced Case-mix and Higher 20,000 200 ICU/C
Slide 14: Surgery Count
Surgery Count Surgery Count +26% (Total Surgery Count) 7000 Total: 6,320 302 6000 +11% Total: 5,026 416 (Total Surgery Count) 299 303 5000 146 176 159 696 198 363 4000 589 537 652 645 3000 Total: 1,680 Total: 1,608 1341 Total: 1,446 1190 2000 53 52 64 62 79 99 43 26 73 63 53 138 64 85 185 156 1000 1
Slide 15: Annual Snapshot – FY26
Annual Snapshot – FY26 FY26 Revenue FY26 EBITDA FY26 EBITDA Margin FY26 PAT Rs Rs173.5 130 CrCr(+10% (+42%YoY) YoY) Rs Rs 35.3 130 Cr (+10% (+42% YoY) YoY) Rs 130 20% Cr (+10% YoY) Rs Rs 16.7 130 Cr (+10% (+58% YoY) YoY) VsRs Vs Rs121.8 120 CrCrininFY25 FY25 Vs Rs Vs Rs24.8 120 Cr Cr in in FY25 FY25
Slide 16: Annual Profit and Loss Summary
Annual Profit and Loss Summary Standalone (₹ in Lakhs) Consolidated (₹ in Lakhs) Particulars FY25* FY26 YoY% Particulars FY25* FY26 YoY% Revenue from operations 12,178 17,320 42% Revenue from operations 12,178 17,350 42% Material costs (2,786) (3,881) 39% Material costs (2,786) (3,881) 39% Employee
Slide 17: Balance Sheet (Standalone)
Balance Sheet (Standalone) (₹ in Lakhs) Equity and Liabilities FY25* FY26 Assets FY25* FY26 I. EQUITY III. Assets 1. Shareholder's funds 1. Non-current assets (a) Share capital 1,968 1,968 (a) Property, plant and equipment 10,342 10,990 (b) Reserves and surplus 6,176 7,884 (b) Non-current investment
Slide 18: Balance Sheet (Consolidated)
Balance Sheet (Consolidated) (₹ in Lakhs) Equity and Liabilities FY25* FY26 Assets FY25* FY26 I. EQUITY III. Assets 1. Shareholder's funds 1. Non-current assets (a) Share capital 1,968 1,968 (a) Property, plant and equipment 10,358 10,999 (b) Reserves and surplus 6,131 7,797 (b) Non-current investme
Slide 19: Consistent Value Creation Across Key Metrics
Consistent Value Creation Across Key Metrics Revenue (₹ in Lakhs) EBITDA (₹ in Lakhs) and Margin % IPD-OPD Revenue (₹ in Lakhs) 20,000 28% CAGR 4,000 20,000 20% 20% 27% CAGR IPD 14,460 15,000 3,000 15,000 33% CAGR OPD 19% 19% 9,909 10,000 7,061 10,000 2,000 17% 5,628 6,128 5,000 1,970 2,643 840 942
Slide 20: Driving Better Assets Monetization
Driving Better Assets Monetization Super-Specialty Hospital Unit ARPOB (in ₹) Bed Capacity and Occupancy % Super Specialty Unit: FY26 25,000 66% 65% 60% 61% 56% ARPOB increased due to Higher 300 revenue realization, Enhanced 20,000 Case-mix and Higher 250 ICU/Critical care utilization. 15,000 200 Ho
Slide 21: Unlocking Value Shareholder Snapshot
Unlocking Value Shareholder Snapshot 20
Slide 22: Delivering Consistent Shareholder Returns
Delivering Consistent Shareholder Returns Stock Info Share Price History BSE Scrip Code SME: 543943 Shares Outstanding 1,96,77,300 300 52-Week Range (INR) 90 - 257 Free Float (%) 38.83% 246 Market Cap (INR Cr) 484 250 FY26 EPS (INR) 8.47 +143% Returns +39% CAGR Net D/E (FY26) 0.46 Since Listing In L
Slide 23: Vision and Strategic Partnership
Vision and Strategic Partnership * Actual photo of Asarfi Hospital. 22
Slide 24: Scaling Operations: Vision for 2028 and Beyond
Scaling Operations: Vision for 2028 and Beyond Capacity Expansion and Consolidation Increasing bed capacity in the Super-specialty hospital from 285 to 350, contingent upon demand. Expanding bed capacity in the Cancer hospital from 65 to 150 (+85) by the end of FY27. Vision 2028 Gearing up for
Slide 25: Partnering for Growth: Multi-Organ Transplant Initiative
Partnering for Growth: Multi-Organ Transplant Initiative Partnership Overview – Q2’FY26 Project Status Multi-Organ Transplant Unit • A dedicated floor has been allocated for the transplant unit, with Asarfi Hospital Gleneagles Hospital consultation and diagnostic services to begin by Q1’FY27. Jharkh
Slide 26: Asarfi Hospital At A Glance
Asarfi Hospital At A Glance * Actual photo of Asarfi Hospital. 25
Slide 27: Asarfi Hospital: Leading Healthcare Player In Jharkhand
Asarfi Hospital: Leading Healthcare Player In Jharkhand Healthcare Excellence Since 2005 20+ Years of Experience Serving Dhanbad and neighboring areas for 20 years with affordable, best-in-class healthcare facilities. Operating two hospitals with 330 total beds across Super- Specialty and Cancer C
Slide 28: Journey Over The Years
Journey Over The Years 2005 2008 2016 2017 2022 2023 2024 2025 2026 Incorporation IPD Dept Expansion Expansion Cancer hospital IPO Cancer hospital Strategic Tech Phase 1 Phase 2 construction operationalised partnership Upgradation 2005-2009: Foundation 2016-2024: Expansion and IPO 2025-2026 and Beyo
Slide 29: Our Departments
Our Departments Paediatrics & Obstetrics & Cardiology Neurosciences General medicine General Surgery Neonatology Gynaecology Gastroenterology Orthopaedics Burn & Plastic Surgery Oncology Nephrology Urology Ophthalmology ENT Day Care services Dental Sciences Physiotherapy Emergency Nutrition & Dietet
Slide 30: Backed By Cutting-Edge Infrastructure and Facilities
Backed By Cutting-Edge Infrastructure and Facilities Asarfi Hospital, Dhanbad 285 Beds | ₹23,020 ARPOB | 56% Occupancy | ALOS 4.2 Days Established in 2005 Specialty in Cardiology, General Medicine and Philips Azurion 5 M12 Neurology (~60% Revenues) Image-Guided Therapy System Facilities: Full-
Slide 31: Competitive Strengths
Competitive Strengths Concentric Impact Regional Advantage Technology Leadership 30 Lakh+ Eastern India’s healthcare Equipped with Jharkhand’s first Population Served market offers a compelling and most advanced Linear Eastern India growth opportunity, Accelerator radiation machine- underpinned
Slide 32: A Scalable Regional Healthcare Leader
A Scalable Regional Healthcare Leader Robust financial performance with 28% Revenue CAGR in last 4 years, 42% YoY Revenue 0`` Growth in FY26, 20% EBITDA Margins, 10% PAT Margins and 17% ROCE as of FY26. In Q4’FY26, Revenue grew by 29% YoY with 17% EBITDA Margins and 9% PAT Margins. Asarfi Hospital i
Slide 33: Key Developments During The Year
Key Developments During The Year • Upgraded existing Cath-Lab with Philips Azurion 5 M12 Image Guided Therapy System which has been operationalized in March 2026, enhancing interventional cardiology capabilities and enabling improved cardiac diagnostic and therapeutic care delivery. • Asarfi Cancer
Slide 34: Leadership Team
Leadership Team Harendra Singh Udai Pratap Singh Sukanti Kumar Das Promoter & CFO Promoter & MD Non-Executive Director • A visionary entrepreneur inspired by • Started his career in 2017, he is a • Renowned Consultant Gynaecologist the Company’s Purpose—Health for All. process and system driven pers
Slide 35: Thank You
Thank You Contact Details: Mr. Udai Pratap Singh Managing Director (MD) Email Id - cs@asarfihospital.com ASARFI HOSPITAL LIMITED | Baramuri, B Polytechnic, Dhanbad, Jharkhand 828130 | CIN - L85110JH2005PLC011673 | cs@asarfihospital.com | www.asarfi.in 34